BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, Cosgrove M, Fagbemi A, Fell J, Chong S, Zamvar V. Use of Infliximab Biosimilar Versus Originator in a Paediatric United Kingdom Inflammatory Bowel Disease Induction Cohort. J Pediatr Gastroenterol Nutr. 2018;. [PMID: 29697550 DOI: 10.1097/mpg.0000000000002011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol 2019;12:1756284819842748. [PMID: 31019554 DOI: 10.1177/1756284819842748] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
2 Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027 [PMID: 30254406 DOI: 10.3748/wjg.v24.i35.4021] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
4 Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis 2020;21:610-20. [PMID: 32920972 DOI: 10.1111/1751-2980.12940] [Reference Citation Analysis]
5 Scavone C, Sessa M, Clementi E, Corrao G, Leone R, Mugelli A, Rossi F, Spina E, Capuano A. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs 2018;32:607-17. [PMID: 30341487 DOI: 10.1007/s40259-018-0313-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
7 Cohen SB, Radominski SC, Kameda H, Kivitz AJ, Tee M, Cronenberger C, Zhang M, Hackley S, Rehman MI, von Richter O, Alten R. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial. BioDrugs 2020;34:197-207. [PMID: 31939063 DOI: 10.1007/s40259-019-00403-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]